2. GPCR/G Protein Neuronal Signaling
  3. Amylin Receptor CGRP Receptor
  4. KBP-066A

KBP-066A is a long-acting dual amylin and calcitonin receptor agonist. KBP-066A can activate the CTR and AMY-R potently, with no off-target activity. KBP-066A reduces fasting blood glucose levels, fasting insulin levels, and body weight in diabetic rat models. KBP-066A can be used for the research of type 2 diabetes mellitus, obesity.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

KBP-066A

KBP-066A Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

KBP-066A Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

KBP-066A is a long-acting dual amylin and calcitonin receptor agonist. KBP-066A can activate the CTR and AMY-R potently, with no off-target activity. KBP-066A reduces fasting blood glucose levels, fasting insulin levels, and body weight in diabetic rat models. KBP-066A can be used for the research of type 2 diabetes mellitus, obesity[1].

In Vitro

KBP-066A (0-25 μM) binds to AMY3R in a concentration-dependent manner[1].
KBP-066A activates CTR (U20S CALCR) and AMY3R (CHO K1 CALCR RAMP3) cells with no off-target activity on tested calcitonin-like receptors[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

KBP-066A Related Antibodies
In Vivo

KBP-066A (1-4 nmol/kg; s.c.; every third day; 4 weeks) induces significant, dose-dependent body weight loss and improves glycemic control in obese rats[1].
KBP-066A (0.75-3 nmol/kg; s.c.; every third day; 8 weeks) improves glycemic status in diabetic ZDF rats[1].
KBP-066A (0.5-36 nmol/kg; s.c.; single dose) has a dose-dependent acute effect on reducing food intake and body weight in obese rats, with longer duration at higher doses[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Sprague Dawley (male, 5-6 weeks old at arrival, baseline weight 528.2 ± 27.9 g at study start, obese via 60 kcal% fat high-fat diet for 20 weeks)[1]
Dosage: 1, 2, 4 nmol/kg
Administration: s.c.; every third day; 4 weeks
Result: Reduced body weight tAUC to 2584 ± 7, 2452 ± 6, 2458 ± 8 g days⁻¹ vs. vehicle 2773 ± 4 g days⁻¹.
Reduced accumulated food intake tAUC to 617 ± 10, 518 ± 6, 532 ± 10 g days⁻¹ vs. vehicle 811 ± 11 g days⁻¹.
Reduced perirenal adipose tissue in 2 and 4 nmol/kg groups.
Improved oral glucose tolerance (non-significant iAUC vs. vehicle).
Reduced plasma insulin iAUC and HOMA-IR significantly.
Animal Model: Zucker Diabetic Fatty (ZDF) (male, 5-6 weeks old at arrival, baseline weight 334.1 ± 15.5 g, baseline fasting blood glucose 14 ± 5.1 mM, baseline plasma insulin 8.0 ± 3.9 ng/mL)[1]
Dosage: 0.75, 1.5, 3 nmol/kg
Administration: S.c.; every third day; 8 weeks
Result: Reduced fasting blood glucose tAUC to 6180 ± 67, 6405 ± 89, 6409 ± 122 vs. vehicle 6475 ± 103.
Reduced accumulated food intake tAUC to 3815 ± 135, 3134 ± 111, 2898 ± 61 g*days⁻¹ vs. vehicle 4453 ± 123 g*days⁻¹.
Reduced HbA1c and significantly improved oral glucose tolerance iAUC at 3 nmol/kg dose.
Showed no significant body weight reduction.
Molecular Weight

4173.76

Formula

C182H303N47O60S2
Sequence

Ac-Cys-Ser-Asn-Leu-Ser-Thr-Cys-{Aib}-Leu-Gly-{Lys(2OEG-γGlu-C18 diacid)}-Leu-Ser-Gln-Asp-Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-Lys-Thr-Asp-Val-Gly-Ala-Asn-Ala-Pro-NH2
Sequence Shortening

Ac-CSNLSTC-{Aib}-LG-{K(2OEG-γGlu-C18 diacid)}-LSQDLHRLQTYPKTDVGANAP-NH2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

KBP-066A Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

KBP-066AAmylin ReceptorCGRP ReceptorAMYRCalcitonin gene-related peptide receptorcalcitonin receptorU20S CALCR cellsCHO K1 CALCR RAMP3 cellstype 2 diabetes mellituscalcitonin-like receptorsAMY3Robese high-fat diet rat modelsamylin receptorZucker Diabetic Fatty rat modelsobesityInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
KBP-066A
Cat. No.:
HY-P11584
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.